1. Fletcher A, Sherry S, Alkjaersig N, et al. The maintenance of a sustained thrombolytic state in man: II. Clinical observations on patients with myocardial infarction and other thromboembolic disorders. J Clin Invest1959;38:11-11.
2.
2. Sherry S. The history and development of thrombolytic therapy. In: Camerota AJ, ed. Thrombolytic Therapy for Peripheral Vascular Disease. Philadelphia: JB Lippincott Co; 1995:67-67.
3.
3. McNicol G. The fibrinolytic system. Postgrad Med J1973;49(suppl):10-10.
4.
4. Bick R. Physiology of hemostasis. In: Bick R, ed. Disorders of Hemostasis and Thrombosis: Clinical and Laboratory Practice. Chicago: ASCP Press; 1992:1-1.
5.
5. Bick R. Physiology of hemostasis and thrombosis. In: Disorders of Hemostasis and Thrombosis: Principles of Clinical Practice. New York: Thieme; 1985:1-1.
6.
6. Aoki N, Moroi M, Matsuda M. The behavior of alpha-2-plasmin inhibitor in fibrinolytic states. J Clin Invest1977;60:361-361.
7.
7. Van de Werf F CC, Luyten A, Houbracken K, et al. Safety assessment of a single bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: The ASSENT-1 trial. Am Heart J1999;137:786-786.
8.
8. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomized trial. Lancet1999;354:716-716.
9.
9. Cannon CP GC, McCabe CH, Adgey AAJ, et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction. Results of the TIMI lOB trial. Circulation1998;98:2805-2805.
10.
10. Johnson A, McCarty W. The lysis of artificially induced intravascular clots in man by intravenous infusion of streptokinase. J Clin Invest1959;38:1627-1627.
11.
11. Jackson KW, Tang J. Complete amino acid sequence of streptokinase and its homology with serine proteases. Biochemistry1982;21:6620-6620.
12.
12. Medved LV, Solovjov DA, Ingham KC. Domain structure, stability and interactions in streptokinase. Eur J Biochem1996;239:333-333.
13.
13. Parrado J, Conejere-Lara F, Smith RA, et al. The domain organization of streptokinase: Nuclear magnetic resonance, circular dichroism, and functional characterization of proteolytic fragments. Protein Science1996;5:693-693.
14.
14. Damaschun G, Damaschun H, Gast K, et al. Streptokinase is a flexible multidomain protein. Eur Biophys J1992;20:355-355.
15.
15. Malke H, Steiner K, Gase K, et al. The streptokinase gene: Alleic variation, genomic environment and expression control. Dev Biol Stand1995;85:183-183.
16.
16. Leopold J, Keaney J, Loscalzo J. Pharmacology of thrombolytic agents. In: Localzo J, Schafer A, eds. Thrombosis and Hemorrhage. Baltimore: Williams and Wilkins;1998:1215-1215.
17.
17. Reddy KN, Markus G. Mechanism of activation of human plasminogen by streptokinase. Presence of an active center in streptokinase-plasminogen complex. J Biol Chem1972;247:1683-1683.
18.
18. Summaria L, Wohl RC, Boreisha IG, et al. A virgin enzyme derived from human plasminogen. Specific cleavage of the arginyl-560-valyl peptide bond in the diisopropoxoyphosphinyl virgin enzyme by plasminogen activators. Biochemistry1982;21:2056-2056.
19.
19. Brommer EJ, Meijer P. Thrombin generation induced by the intrinsic or extrinsic pathway is accelerated by streptokinase, independent of plasminogen. Thromb Haemost1993;70:995-995.
20.
20. Gouin I, Lecompte T, Morel MC, et al. In vitro effects of plasmin on human platelet function in plasma. Inhibition of aggregation caused by fibrinogenolysis. Circulation1992;85:935-935.
21.
21. Figueredo V, Amidon T, Wolfe C. Thrombolysis after acute myocardial infarction: Who should be added to inclusion criteria?Postgrad Med1994;96:30-30.
22.
22. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Long-term effects of intravenous thrombolysis in acute myocardial infarction: Final report of the GISSI Study. Lancet1987;398:871-871.
23.
23. Lee H, Yule S, McKenzie A, et al. Hypersensitivity reactions to streptokinase in patients in patients with high pre-treatment antistreptokinase antibody and neutralisation titres. Eur Heart J1993;14:1640-1640.
24.
24. Fears R. Development of anisoylated plasminogen-streptokinase activator complex from the acyl enzyme complex. Semin Thromb Hemost1989;15:129-129.
25.
25. Smith R, Dyse R, English P. Acyl-enzymes as thrombolytic agents in a rabbit model of venous thrombosis. Thromb Haemost1982;47:269-269.
26.
26. Smith R, Dupe R, English P, et al. Fibrinolysis with acylenzymes: A new approach to thrombolytic therapy. Nature1981;290:505-505.
27.
27. Green J, Dupe R, Smith R, et al. Comparison of the hypotensive effects of streptokinase-(human) plasmin activator complex and BRL 26921 (p-anisoylated streptokinase-plasminogen activator complex) in the dog after high dose bolus administration. Thromb Res1984;36:29-29.
28.
28. Ferres H. Preclinical pharmacological evaluation of anisoylated plasminogen streptokinase activator complex (review). Drugs. 1987;33S:33S-33S.
29.
29. Fears R, Ferres H, Standring R. The protective effect of acylation on the stability of anisoylated plasminogen streptokinase activator complex in human plasma. Drugs1987;33(suppl):57-57.
30.
30. Lee H, Cross S, Davidson R, et al. Raised levels of antistreptokinase antibody and neutralization titres from 4 days to 54 months after administration of streptokinase or anistreplase. Eur Heart J1993;14:84-84.
31.
31. Johnson E, Gregeen R. An interim report of the efficacy and safety of anisoylated plasminogen activator complex (APSAC). Drugs1987;33(suppl 3):298-298.
32.
32. Collen D. Report of the Subcommittee on Fibrinolysis; San Diego, CA, July 13, 1985. Thromb Haemost1985;54:893-893.
33.
33. Husain S, Gurewich W, Lipinski B. Purification and partial characterization of a single-chain high-molecularweight from of urokinase from human urine. Arch Biochem Biophys1983;220:31-31.
34.
34. Wun T, Schleuning W, Reich E. Isolation and characterization of urokinase from human plasma. J Biol Chem1982;257:3276-3276.
35.
35. Wun T, Ossowski L, Reich E. A proenzyme form of human urokinase. J Biol Chem1982;257:7262-7262.
36.
36. Riccio A, Grimaldi G, Verde P, et al. The human urokinase-plasminogen activator gene and its promoter. Nucleic Acids Res1985;13:2759-2759.
37.
37. Collen D, Zamarron C, Lijnen H, et al. Activation of plasminogen by prourokinase II. Kinetics. J Biol Chem. 1986;621:1259-1259.
38.
38. Pannell R, Gurewich V. Pro-urokinase: A study of its stability in plasma and of a mechanism for its selective fibrinolytic effect. Blood. 1986;67:1215-1215.
39.
39. Diefenbach C, Erbel R, Pop T, et al. Recombinant singlechain urokinase-type plasminogen activator during acute myocardial infarction. Am J Cardiol. 1988;61:966-966.
40.
40. Rijken D, Wijngaards G, Zaal-De Jong M, et al. Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta. 1979;580:140-140.
41.
41. Rijken D, Wijngaards G, Welbergen J. Relationship between tissue plasminogen activator and the activities in blood and vascular wall. Thromb Res1980;18:815-815.
42.
42. Collen D, Rijken D, Van Damme J, et al. Purification of human tissue-type plasminogen activator in centigrams and its conditioning for use in vivo. Thromb Haemost1982;48:294-294.
43.
43. Pennica D, Holmes W, Kohr W, et al. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature1983;301:214-214.
44.
44. Linjen H, Collen D. Mechanism of plasminogen activation by mammalian plasminogen activators. Enzyme. 1988;40:90-90.
45.
45. Lamba D, Bauer M, Huber R, et al. The 2.3 A crystal structure of the catalytic domain of recombinant twochain human tissue-type plasminogen activator. J Mol Biol1996;258:117-117.
46.
46. Verstraete M, Su C, Tanswell P, et al. Pharmacokinetics and effects on fibrinolytic and coagulant parameters of two doses of recombinant tissue-type plasminogen activator in healthy volunteers. Thromb Haemost1986;56:1-1.
47.
47. Tanswell P, Tebbe U, Neuhaus K, et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. JAm Coll Cardiol1992;19:1071-1071.
48.
48. Berger HJ, Pizzo S. Preparation of polyethylene glycoltissue plasminogen activator adducts that retain functional activity: Characteristics and behavior in three animal species. Blood1988;71:1641-1641.
49.
49. Burck P, Berg D, Warrick M, et al. Characterized of a modified human tissue plasminogen activator comprising a kringle-2 and a protease domain. J Biol Chem1990;265:5170-5170.
50.
50. Cody R. Results from late breaking trials sessions ACC '97. JAm Coll Cardiol1997;30:1-1.
52. Keyt B, Paoni P, Refino C, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Naol Acad Sci USA1994;91(3670).
53.
53. Rudolf J, Grond M, Prince W, Schmulling S, Heiss W. Evidence of anaphylaxis after alteplase infusion. Stroke1999;30:1142-1142.
54.
54. Investigators of the International Joint Efficacy Comparison of Thrombolytics (INJECT). Randomized, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): Trial to investigate equivalence. Lancet1995;346:329-329.
55.
55. Keyt B, Paoni N, Refino C, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA. 1994;91:3670-3670.
56.
56. Paoni N, Keyt B, Refino C, et al. A slow clearing, fibrin specific, PAI-1 resistant variant of tPA (T103N, KHRR 296-299). Thromb Haemost1993;70:307-307.
57.
57. Tanswell P, Tebbe U, Neuhaus KL, et al. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusion in acute myocardial infarction. JAm Coll Cardiol1992;19:1071-1071.
58.
58. Cannon C, McCabe C, Gibson C, et al. TNK-tissue plasminogen activator in acute myocardial infraction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation1997;95:351-351.
59.
59. Hoffmeister HM, Szabo S, Kastner C, et al. Thrombolytic therapy in acute myocardial infarction: Comparison of procoagulant effects of streptokinase and alteplase regimens with focus on kallikrein system and plasmin. Circulation1998;98:2527-2527.
60.
60. Rapold H. Promotion of thrombin activity by thrombolytic therapy without simultaneous anticoagulation. Lancet1990;1:481-481.
61.
61. Eisenberg P, Miletich J, Sobel B, et al. Factors responsible for the differential procoagulant effects of diverse plasminogen activators in plasma. Fibrinolysis1991;5:217-217.
62.
62. Davies M, Thomas A, Knapman P. Intra-myocardial platelet aggregation in patients with unstable angina suffering sudden ischemic cardiac death. Circulation1986;73:418-418.
63.
63. Nicolini FA, Lee P, Rios G, Kotte-Marchant K, Topol E. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation1994;89:1802-1802.
64.
64. Roux S, Tschoff T, Kuhn H, Steiner B, Hadvary P. Effects of heparin, aspirin, and synthetic glycoprotein Ilb/Illa receptor antagonist on coronary reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog. J Pharm Exper Ther1993;264:501-501.
65.
65. Ohman EM, Kleiman N, Gacioch G, et al. Combined accelerated tissue-plasminogen activator and glycoprotein Ilb/Illa integrin receptor blockade with Integrilin in acute myocardial infarction: Results of a randomized, placebocontrolled dose-ranging trial. Circulation1997;95:846-846.
66.
66. Moliterno DJ, Harrington RA, Krucoff MW, et al. More complete and stable reperfusion with platelet Ilb/IlIa antagonism plus thrombolysis for AMI: The PARADIGM trial [abstract]. Circulation1996;94(suppl I):1-553.
67.
67. Rote W, Mu D, Bates E, Nedelman M, Lucchesi B. Prevention of rethrombosis after coronary thrombolysis in chronic canine model: Adjunctive therapy with monoclonal antibody 7E3 F(ab') 2 fragment. J Cardiovasc Pharm1994;23:194-194.
68.
68. Cronberg S. Effect of fibrinolysis on adhesion and aggregation of human platelets. Thromb Diath Haemorr1968;19:474-474.
69.
69. Terres W, Uranus S, Mathey DG, Bleifeld W. Effect of streptokinase, urokinase and tissue plasminogen activator on platelet aggregability and stability of platelet aggregates. Cardiovasc Res1990;67:1175-1175.
70.
70. Fitzgerald D, Catella F, Roy L, Fitzgerald G. Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation1988;77:142-142.
71.
71. Kleiman N, Ohman M, Califf R, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab following thrombolytic therapy: Results of the TAMI 8 pilot study. JAm Coll Cardiol1993;22:381-381.
72.
72. White H, Van De Werf F. Thrombolysis for acute myocardial infarction. Circulation1998;97:1632-1632.
73.
73. Coulter S, Cannon C, Ault K, et al. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: Results from TIMI (Thrombolysis in Myocardial Infarction) 14. Circulation2000;101:2690-2690.
74.
74. Gurbel PA, Serebruany VL, Shustov AR, et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. J Am Coll Cardiol1997;31:1466-1466.
75.
75. Nordt TK, Moser M, Kohler B, et al. Augmented platelet aggregation as predictor of reocclusion after thrombolysis in acute myocardial infarction. Thromb Haemost1998;80:881-881.
76.
76. Herrick J. Clinical features of sudden obstruction of the coronary arteries. J Am Med Assoc1912;59:2015-2015.
77.
77. DeWood M, Spores J, Notshe R, et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med1980;303:897-897.
78.
78. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med1993;329:673-673.
79.
79. Chesebro JH, Knaterud G, Roberts R, et al. Thrombolysis in acute myocardial infarction (TIMI) trial, phase 1: A comparison between intravenous plasminogen activator and intravenous streptokinase. Circulation1987;76:142-142.
80.
80. Verstraete M, Bleifeld W, Bory M, et al. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet1985;1:842-842.
81.
81. Verstraete M, Bleifeld W, Brower R, et al. Double blind randomized trial of intravenous tissue-type plasminogen activator versus placebo in acute myocardial infarction. Lancet1985;2:956-956.
82.
82. Sheehan FH, Brawnwald E, Canner P, et al. The effect of intravenous thrombolytic therapy on left ventricular function: A report on tissue-type plasminogen activator and streptokinase from the thrombolysis in myocardial infarction (TIMI phase I) trial. Circulation1987;75:817-817.
83.
83. PRIMI Trial Study Group. Randomized double-blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction. Lancet1989;1:863-863.
84.
84. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI)-1. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet1986;1:397-397.
85.
85. Second International Study of Infarct Survival (ISIS-2) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet1988;2:349-349.
86.
86. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: Preliminary report of a placebo-controlled clinical trial. Lancet1988;1:545-545.
87.
87. Wilcox R, vanderLippe G, Olsson C, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo-Scandinavia study of early thrombolysis (ASSET). Lancet1988;2:525-525.
88.
88. Morrison U, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA2000;283:2686-2686.
89.
89. Carnendran L, Steinberg J. Does an open infarct-related artery after myocardial infarction improve electrical stability. Prog Cardiovasc Dis2000;42:439-439.
90.
90. Six A, Louwerenburg H, Braams R, et al. A double-blind randomized multicenter dose-ranging trial of streptokinase in acute myocardial infarction. Am J Cardiol1990;65:119-119.
91.
91. Granger CB, White HD, Bates ER, Ohman EM, Califf RM. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol1994;74:1220-1220.
92.
92. Gruppo Italiano per lo Studio del Streptochinasi nel'Infarto Miocardico GISSI-2, and International Study Group. Six-month survival in 20,891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Eur Heart J1992;123:1692-1692.
93.
93. The ISAM Trial Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity, and infarct size at 21 days. N Engl J Med1986;314:1465-1465.
94.
94. EMERAS (Estudio Multicentrico Estrepoquinasa Repulicas del America del Sur) Collaborative Group. Randomized trial of late thrombolysis in patients with suspected acute myocardial infarction. Lancet1993;342:767-767.
95.
95. Fibrinolytic Trialist's Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet1994;343:311-311.
96.
96. The TIMI Study Group. Thrombolysis in Myocardial Infarction (TIMI) trial phase I findings. N Engl J Med1985;312:932-932.
98. Neuhaus R, VonEssen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rtPA-APSAC patency study (TAPS). JAm Coll Cardiol1992;19(5):885-885.
99.
99. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: A factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet1990;336:65-65.
100.
100. Third International Study of Infarct Survival (ISIS-3) Collaborative Group. ISIS3: A randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet1992;339:753-753.
101.
101. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med1993;329:1615-1615.
102.
102. Cannon CP, McCabe CH, Diver DJ, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. JAm Coll Cardiol1994;24:1604-1604.
103.
103. The Continuous Infusion versus Double-bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med1997;337:1124-1124.
104.
104. Mark DB, Hlatky M, Califf R, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared to streptokinase for acute myocardial infarction. N Engl J Med1995;332:1418-1418.
105.
105. Gurwitz JH, Gore JM, Goldberg RJ, et al. Risk for intracranial hemorrhage after tissue plasminogen activator treatment of acute myocardial infarction. Ann Intern Med1998;129:597-597.
106.
106. Smalling R, Bode C, Kalbfleisch J, et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation1995;91:2725-2725.
107.
107. Bode C, Smalling RW, Berg G, et al. Randomized comparison of coronary thrombolysis achieved with doublebolus reteplase (recombinant plasminogen activator) and front-loaded alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation1996;94:891-891.
108.
108. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-Ill) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med1997;337:1118-1118.
109.
109. Fox N, Cannon C, Berioli S, et al. Rates of serious bleeding events requiring transfusion in AMI patients treated with TNK-tPA. JAm Coll Cardiol1999;33:279-279.
110.
110. Barron HV, Fox N, Berioli S, et al. Comparison of intracranial hemorrhage rates in patients treated with rtPA and TNKt-PA: Impact of gender, age and low body weight. Circulation1999;100:I-I.
111.
111. den Heijer P, Vermeer F, Ambrosioni E, et al. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: A double-blind, randomized angiographic trial of lanoteplase versus reteplase. Circulation1998;98:2117-2117.
112.
112. The InTIME-II Investigators. Intravenous NPA for the treatment of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J2000;21:2005-2005.
113.
113. Markwardt F. Hirudin and its derivatives as anticoagulant agents. Thromb Haemost1991;66:141-141.
114.
114. White H, Aylward P, Frey M, et al. Randomized, doubleblind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation1997;96:2155-2155.
115.
115. Jang IK, Giugliano RP, Massey T, et al. A randomized, blinded study of two doses of Novastin (brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue-plasminogen activator (accelerated administration) in acute myocardial infarction: Rationale and design of the myocardial infarction using Novastin and T-PA (MINT) study. J Thromb Thrombol1998;5:49-49.
116.
116. Fung A, Lorch G, Cambier P, et al. Efegetran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patietns with acute myocardial infarction. Am Heart J1999;138:696-696.
117.
117. Thrombin Inhibition in Myocardial Ischemia (TRIM) Group. A low molecular weight, selective thrombin inhibitor, inogatran, vs heparin, in unstable coronary artery disease in 1209 patients: A randomized, dose-finding study. Eur Heart J1997;18:1416-1416.
119. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI 4) trial. Circulation1999;99:2720-2720.
120.
120. The PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein Ila/IIlb inhibitor lamifiban: Results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM). JAm Coll Cardiol1998;32:2003-2003.
121.
121. Topol EJ. Toward a new frontier in myocardial perfusion therapy: Emerging platelet preeminence. Circulation1998;97:211-211.
122.
122. Strategies for Patency Enhancement in the Emergency Department (SPEED) Trial Group. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction: Strategies for Patency Enhancement in the Emergency Department (SPEED). Circulation2000;101:27-88.
123.
123. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) V Investigators. A comparison of heparin plus full, bolus dose reteplase with half-dose reteplase plus abciximab plus heparin in patients with acute myocardial infarction. Lancet2001;357:1905-1905.
124.
124. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomized trial in acute myocardial infarction. Lancet2001;358:605-605.
125.
125. McLean J. The thromboplastic action of cephalin. Am J Physiol1912;41:250-250.
126.
126. Weitz J, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest1990;86:385-385.
127.
127. Bleich S, Nichols T, Schumacher R, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol1990;66:1412-1412.
128.
128. Hsia J, Hamilton W, Kleiman N, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med1990;323:1433-1433.
129.
129. Giugliano RP, Cutler S, Llevadot J. Risk of intracranial hemorrhage with accelerated tPA: Importance of heparin dose. Circulation1999;100:1-1.
130.
130. Ryan T, EM. A, Brooks N, et al. Update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol1999;34:890-890.
131.
131. Kontny F, Dale J, Abildgaard U, et al. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular mural thrombus formation and arterial embolism after acute myocardial infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study. JAm Coll Cardiol1997;39:962-962.
132.
132. Glick A, Kornowski R, Michowich Y, et al. Reduction of reinfarction and angina with the use of low-molecularweight heparin therapy after streptokinase (and heparin) in acute myocardial infarction. Am J Cardiol1996;77:1145-1145.
133.
133. Vu T, Hung D, Wheaton V, et al. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell1991;64:1057-1057.
134.
134. Rydel T, Ravichandran K, Tulinsky A, et al. The structure of a complex of recombinant hirudin and human-thrombin. Science1990;249:277-277.
135.
135. Lee L. Initial experience with hirudin and streptokinase in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 6 trial. Am J Cardiol1995;75:7-7.
136.
136. Antman EM. Hirudin in acute myocardial infarction: Thrombolysis and thrombin in myocardial infarction (TIMI) 9b trial. Circulation1996;94:911-911.
137.
137. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med1996;335:775-775.
138.
138. Neuhaus K, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HITT-III) study: A study of the Arbeirsgerneinschaft Leitender Kardiologischer Krankenhausarzte (ALKK). Circulation1994;90:1638-1638.
139.
139. Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in acute myocardial infarction: Results of the HIT-4 trial. JAm Coll Cardiol1999;34:966-966.
140.
140. Theroux P, Perez-Villa F, Waters D, et al. Randomized double-blind comparison of two doses of Hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation1995;91:21-32.
141.
141. White HD, Aylward PE, Frey MJ, et al. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation. 1997;96:21-55.
142.
142. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: The HERO-2 randomized trial. Lancet2001;358:18-55.
143.
143. Fieschi C, Argentino C, Weschler L, et al. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours. J Neurol Sci1989;91:311-311.
144.
144. del Zoppo G, Poeck P, Pessin M. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol1992;32:78-78.
145.
145. Siesjo B. Pathophysiology and treatment of focal cerebral ischemia: I: Pathophysiology. J Neurosurg1992;77:169-169.
146.
146. Levine S, Brott T. Thrombolytic therapy in cerebrovascular disorders. Prog Cardiovasc Dis1992;34:235-235.
147.
147. Brott T, Broderick J, Kothari R. Thrombolytic therapy for stroke. Curr Opin Neurol1994;7:25-25.
148.
148. Wardlaw JM, Warlow C. Thrombolysis in acute ischemic stroke: Does it work?Stroke1992;23:1826-1826.
149.
149. The National Institute of Neurological Disorders and Stroke rtPA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med1995;333:1581-1581.
150.
150. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Stroke Study (ECASS). JAMA1995;274:1017-1017.
151.
151. Hacke W, Kaste M, Fieschi C, et al. Randomized doubleblind intravenous alteplase in acute placebo controlled trial of thrombolytic therapy with ischemic stroke (ECASS II): Second European-Australian Acute Stroke Study Investigators. Lancet1998;352:1245-1245.
152.
152. Clark W, Wissman S, Albers G, et al. Recombinant tissuetype plasminogen acivator (Alteplase) for ischemic stroke 3-5 hours after symptom onset. JAMA1999;282:2019-2019.
153.
153. Clark W, Albers G, Madden K, et al. The rtPA (alteplase) 0 to 6-hour acute stroke trial, Part A (A0276g): Results of a double-blind, placebo-controlled multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke2000;31:811-811.
154.
154. The Multicenter Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med1996;335:145-145.
155.
155. The Australian Streptokinase (ASK) Trial Study Group. Streptokinase for acute ischemic stroke with relationship to time of admission. JAMA 1996;276:961-961.
156.
156. Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin and combination of both in treatment of acute ischemic stroke. Lancet1995;346:1509-1509.
157.
157. del Zoppo G, Higashida R, Furlan R, et al. PROACT: A phase II randomized trial of recombinant prourokinase by direct delivery in acute middle cerebral artery stroke. Stroke1998;29:4-4.
158.
158. Furlan A, Higashida F, Wechsler L, et al. A randomized trial of intra-arterial prourokinase for acute ischemic stroke due to middle cerebral artery occlusion. JAMA1999;282:2003-2003.
159.
159. Wardlaw J, Warlow C, Counsell C. Systematic review of evidence of thrombolytic therapy for acute ischemic stroke. Lancet1997;350:607-607.
160.
160. Hacke W, Brott T, Caplan L, et al. Thrombolysis in acute ischemic stroke: Controlled trials and clinical experience. Neurology1999;53(suppl 4):S3-S3.
161.
161. Albers G, Amarenco P, Easton D, et al. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest2001;119S:300S-300S.
162.
162. Bell WR, Black EB, DeMets D. Urokinase Pulmonary Embolism Trial: Phase I results. JAMA1970;214:2163-2163.
163.
163. Bell WR, Black EB, DeMets D. Urokinase Pulmonary Embolism Trial: Phase II results. JAMA1974;229:1606-1606.
164.
164. Marder V. The use of thrombolytic agents: Choice of patient, drug administration, laboratory monitoring. Ann Intern Med1979;90:802-802.
165.
165. Goldhaber SZ, Kessler C, Heit J, et al. Randomized controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet1988;2:293-293.
166.
166. Immelman E, Jeffrey P. The post-phlebitic syndrome. Pathophysiology prevention and management. Clin Chest Med1984;5:537-537.
167.
167. Arnesen H, Hoiseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis: Results of a prospective trial. Acta Med Scand1982;211:65-65.
168.
168. Elliott M, Immelman E, Jeffrey P, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: An interim report of a prospective trial. Br J Surg1979;66:383-383.
169.
169. Watz R, Savidge G. Rapid thrombolysis and preservation of valvular venous function in high deep vein thrombosis. Acta Med Scand1979;205:293-293.
170.
170. Common H, Seaman A, Rosch J, et al. Deep vein thrombosis treated with streptokinase or heparin: Follow-up of a randomized study. Angiology1976;27:645-645.
171.
171. Johanson L, Nylander G, Hedner U, et al. Comparison of streptokinase with heparin: Late results in the treatment of deep vein thrombosis. Acta Med Scand1979;296:93-93.
172.
172. Kakkar V, Lawrence DA. Hemodynamic and clinical assessment after therapy of acue deep vein thrombosis. Am J Surg1985;10:54-63.
173.
173. Prandoni P, Lensing AW, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med1996;125:1-1.
174.
174. Marder V, Sherry S. Thrombolytic therapy: Current status. N Engl J Med1988;318:1585-1585.
175.
175. Goldhaber SZ, Meyerovitz M, Green D, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med1990;88:235-235.
176.
176. Goldhaber SZ, Haire W, Feldstein M. Alteplase versus heparin in acute pulmonary embolism: Randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet1993;341:507-507.
177.
177. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose alteplase versus conventional alteplase for pulmonary thrombolysis: An international multicenter randomized trial: Bolus Alteplase Pulmonary Embolism Group. Chest1994;106:718-718.
178.
178. Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: Immediate clinical and hemodynamic outcome and one-year follow-up. JAm Coll Cardiol1998;31:1057-1057.
179.
179. Kostantinides S, Tiede N, Geibel A, et al. Comparison of alteplase versus heparin for resolution of major embolism. Am J Cardiol1998;82:966-966.
180.
180. Sharma G, Burleson V, Sasahara A, et al. Effect of thrombolytic therapy on pulmonary blood capillary blood volume in patients with pulmonary embolism. N Engl J Med1980;303:842-842.
181.
181. Tebbe U, Graf A, Kamke W, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J1999;138:39-39.
182.
182. Hyers T, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest2001;119S:176S-176S.
183.
183. Goldhaber SZ. Management of deep vein thrombosis and pulmonary embolism. Clinical Cornerstone2000;2:47-47.
184.
184. Verstraete M, Miller G, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissuetype plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation1988;77:353-353.
185.
185. Dalen JE, Alpert JS. Thrombolytic therapy for pulmonary embolism: Is it effective? Is it safe? When is it indicated?Arch Intern Med1997;157:2550-2550.
186.
186. McConnell M, Solomon S, Rayan M, et al. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol1996;78:469-469.
187.
187. Hirsh J, Hoak J. Management of deep vein thrombosis and pulmonary embolism: A statement for healthcare professionals. Circulation1996;93:2212-2212.
188.
188. Nasraway S, Kabani N, Lawrence K. Thrombolytic therapy for pulmonary embolism: Reversal of shock in the early postoperative period. Pharmacotherapy1994;14:616-616.
189.
189. Severi P, LoPinto G, Poggio R, Andrioli G. Urokinase thrombolytic therapy of pulmonary embolism in neurosurgically terated patients. Surg Neurol1994;42:469-469.
190.
190. Mazeka P, Oakley C. Massive pulmonary embolism in pregnancy treated with streptokinase and percutaneous catheter fragmentation. Eur Heart J1994;15:1281-1281.
191.
191. Kurkciyan I, Meron G, Sterz F, et al. Pulmonary embolism as a cause of cardiac arrest. Arch Intern Med2000;160:1529-1529.
192.
192. Bottinger B, Reim S, Diezel G, Bohrer H, Martin E. Highdose bolus injection of urokinase. Use during cardiopulmonary resuscitation for massive pulmonary embolism. Chest1994;106:1281-1281.
193.
193. Schmitz-Rode T, Janssens U, Duda SH, Erley CM, Gunther RW. Massive pulmonary embolism: Percutaneous emergency treatment by pigtail rotation catheter. JAm Coll Cardiol2000;36(2):375-375.
194.
194. Turpie AG, Levine M, Hirsh J, et al. Tissue plasminogen activator vs heparin in DVT. Results of a randomized trial. Chest1990(172S).
195.
195. Arnesen H, Hoiseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis: Follow-up results of a prospective trial. Act Med Scand1982;211:65-65.
196.
196. Camerota A, Aldridge S, Cohen G, Ball D, Pliskin M, White J. A strategy of aggressive reginal therapy for acute iliofemoral venous thrombosis with contemporary venous thrombectomy or catheterdirected thrombolysis. J Vasc Surg1994;20:244-244.
197.
197. Semba C, Dake M. Iliofemoral deep venous thrombosis: Aggressive therapy with catheter-directed thrombolysis. Radiology1994;191:487-487.
198.
198. Vehaeghe R, Stockx L, Lacroix H, Vermylen J, Baert A. Catheter-directed lysis of iliofemoral vein thrombosis with the use of rtPA. Eur Radiol1997;7:996-996.
199.
199. Bjarnason H, Kruse J, Azinger D, et al. Iliofemoral deep vein thrombosis: Safety and efficacy outcome during 5 years of catheter-directed thrombolytic therapy. J Vasc Intervent Radiol1997;8:405-405.
200.
200. Mewissen M, Seabrook G, Meissner M, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: Report of a national multicenter registry. Radiology1999;211:39-39.
201.
201. Verstraete M, Vermylen J, Donati M. The effect of streptokinase infusion of chronic arterial occlusions and stenosis. Ann Intern Med1971;74:377-377.
202.
202. Cotton L, Flute P, Tsapogas M. Popliteal artery thrombosis treated with streptokinase. Lancet1962;2:1081-1081.
203.
203. Amery A, Deloof W, Vermylen J, Verstracte M. Outcome of recent thromboembolic occlusion of limb arteries treated with streptokinase. Br J Med1970;4:639-639.
204.
204. Sicard G, Schier J, Totty W, et al. Thrombolytic therapy for acute arterial occlusion. J Vasc Surg1985;2:65-65.
205.
205. Hallet J, Greenwood L, Yrizzary J, et al. Statistical determinants of success and complications of thrombolytic therapy for arterial occlusion of lower extremity. Surg Gynecol Obstet1985;161:431-431.
206.
206. Chaise L, Camerota A, Soulen R, et al. Selective intra-arterial streptokinase therapy in the immediate postoperative period. JAMA. 1982;247:2397-2397.
207.
207. Hess H, Ingrisch H, Mietaschk A, et al. Local low-dose thrombolytic therapy of peripheral arterial occlusions. N Engl J Med1982;307:1627-1627.
208.
208. Berni G, Bandyk D, Zierler R, et al. Streptokinase treatment of acute arterial occlusion. Ann Surg1983;198:185-185.
209.
209. Ouriel K, Shortell C, de Weese J, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg1994;19:1021-1021.
210.
210. Ouriel K, Veith F, Sasahara A. Investigators for the Thrombolysis or Peripheral Artery Surgery (TOPAS). A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med. 1998;338:1105-1105.
211.
211. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE Trial. Ann Surg1994;220:251-251.
212.
212. van Breda A, Robison J, Feldman L, et al. Local thrombolysis in the treatment of arterial graft occlusions. J Vasc Surg1984;1:103-103.
213.
213. Gardiner GJ, Koltun W, Kandarpa K, et al. Thrombolysis of occluded femoropopliteal grafts. Am J Roentgenol1986;147:621-621.
214.
214. Belkin M, Belkin B, Bucknam C, Straub J, Lowe R. Intra-arterial fibrinolytic therapy-efficacy of streptokinase vs. urokinase. Arch Surg1986;121:769-769.
215.
215. McNamara T, Fischer J. Thrombolysis of peripheral arterial and graft occlusions: Improved results using highdose urokinase. Am J Roentgenol1985;144:769-769.
216.
216. Heymans S, Venderschueren S, Verhaege R, et al. Outcome and one year follow-up of intrararterial staphylokinase in 191 patients with peripheral arterial occlusions. Thromb Haemost2000;83:666-666.
217.
217. Marder VJ. Thrombolytic Therapy: Foundations and Results. In: Colman R, Hirsh J, Marder VJ, Clowes A, George J, eds. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 4th ed.Philadelphia: Lippincott, Williams & Wilkins;2001:1475-1475.
218.
218. Kroger K, Buss D, Rudofsky G. Retrospective analysis of rtPA thrombolysis combined with PGE1 in patients with peripheral arterial occlusions. Angiology2000;52:377-377.
219.
219. Murr K, Rhoney D, Coplin W. Urokinase in the treatment of intraventricular hemorrhage. Ann Pharmacother1998;32:256-256.
220.
220. Lee W, Hill B, Harris EJ, Semba C, Olcott CI. Surgical intervention is not required for all patients with subclavian vein thrombosis. J Vasc Surg2000;32:57-57.
221.
221. Urschel HC Jr, Razzuk MA. Paget-Schroetter syndrome: What is the best management?Ann Thorac Surg2000;69(6):1663-1663; discussion 1668-1668.
222.
222. Leebeek F, Lameris J, van Buren H, et al. Budd-chiari syndrome, portal vein and mesenteric vein thrombosis in a patient homozygous for factor V Leiden mutation treated by TIPS and thrombolysis. Br J Haematol1998;102:929-929.
223.
223. Bhattacharjya T, Olliff S, Bhattacharlya S, et al. Percutaneous portal vein thrombolysis and endovascular stent for management of post transplant portal venous conduit thrombosis. Transplantation2000;69:2195-2195.
224.
224. Silber H, Khan S, Matloff J, et al. The St. Jude valve. Thrombolysis as the first line of therapy for cardiac valve thrombosis. Circulation1993;87:30-30.
225.
225. Shapira Y, Herz I, Vaturi M, et al. Thrombolysis is an effective and safe therapy in stuck mitral valves in the absence of high-risk thrombi. J Am Coll Cardiol2000;35:1874-1874.
226.
226. Gore JM, Granger C, Simoons ML, et al. Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-1 trial. Global Use of Strategies to Open Occluded Coronary Artery. Circulation1995;92:2811-2811.
